Table 2.
DANCR in tissues/serum/plasma as diagnostic and prognostic biomarkers
| Cancer type | Biomarker type | Specificity | Sensitivity | AUC | Sample | References |
|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | Diagnostic/prognostic | 84.3% | 80.8% | 0.868 | Plasma | 15, 16 |
| Gastric cancer | Diagnostic/prognostic | 67.7% | 64.6% | 0.704 | Tissues | 19, 21 |
| 79.5% | 72.7% | 0.816 | Serum | |||
| Colorectal cancer | Prognostic | NA | NA | NA | Tissues | 23 |
| Breast cancer | Diagnostic/prognostic | NA | NA | NA | Tissues | 30, 31 |
| Lung cancer | Diagnostic/prognostic | NA | NA | 0.927 | Tissues | 39, 40 |
| NA | NA | 0.883 | Plasma | |||
| Osteosarcoma | Prognostic | NA | NA | NA | Tissues | 46 |
| Bladder cancer | Diagnostic | NA | NA | NA | Tissues | 51 |
| Nasopharyngeal carcinoma | Diagnostic/prognostic | NA | NA | NA | Tissues | 55, 58 |
| Papillary thyroid cancer | Diagnostic | 66.2% | 85.3% | 0.823 | Tissues | 59 |
| 82.2% | 81.5% | 0.876 | ||||
| 91.7% | 83.3% | 0.917 |